SC

Suresh Chand Aggarwal

Director DIN 00858828
DIN 00858828 First appointment Jan 2002
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jan 2002
Shareholding value β€’β€’β€’β€’ Premium profile

About Suresh Chand Aggarwal

Data last updated:

Suresh Chand Aggarwal was a Managing Director at K. L. Biotech Private Limited (from 2016) and Director at P.N.Drugs Private Limited (from 2002).

DIN 00858828
First Appointment 29 Jan 2002
Oldest Company Age 25 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
K. L. Biotech Private Limited U24233UP2008PTC035676
Managing Director15 Mar 20162008₹30,631 (FY 2018)Strike Off
P.N.Drugs Private Limited U24232UP2001PTC026138
Director29 Jan 20022001Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
K. L. Biotech Private Limited
P.N.Drugs Private Limited
Premium access

Shareholding and investment profile for Suresh Chand Aggarwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suresh Chand Aggarwal

Suresh Chand Aggarwal was first appointed on 29 Jan 2002 as Director at P.N.Drugs Private Limited. The most recent appointment on record is 15 Mar 2016 at K. L. Biotech Private Limited.

Suresh Chand Aggarwal held 2 earlier board appointments: K. L. Biotech Private Limited (Managing Director, from 15 Mar 2016); P.N.Drugs Private Limited (Director, from 29 Jan 2002).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available